75
Participants
Start Date
June 27, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
Emicizumab
"Participants will receive emicizumab 3 milligrams per kilogram (mg/kg) subcutaneous (SC) injections every week (QW) for the first 4 weeks as loading doses, followed by maintenance doses of emicizumab 3 mg/kg SC once every 2 weeks (Q2W).~During the extension period, participants may remain on maintenance dose of emicizumab 3 mg/kg Q2W, or change their emicizumab maintenance regimen to 1.5 mg/kg once every week (QW) or 6 mg/kg once every 4 weeks (Q4W), if they prefer and if agreed by the investigators."
von Willebrand Factor (VWF) Concentrates
Used according to local labeling or local treatment guidelines.
Factor VIII (FVIII) Concentrates
Used according to local labeling or local treatment guidelines.
von Willebrand Factor (VWF) and Factor VIII (FVIII) Concentrates
Used according to local labeling or local treatment guidelines.
Bypassing Agents
Used according to local labeling or local treatment guidelines.
RECRUITING
UZ Leuven Gasthuisberg, Leuven
RECRUITING
Hospital Universitario la Paz, Madrid
RECRUITING
Hospital Universitario Virgen del Rocio, Seville
RECRUITING
Gerinnungszentrum Rhein-Ruhr;Gerinnungsambulanz, Duisburg
RECRUITING
AOU Careggi, Florence
RECRUITING
Universitätsklinikum Bonn, Bonn
RECRUITING
Hopital Claude Huriez - CHU Lille, Lille
RECRUITING
Hämophiliezentrum Med. Klinik III/Institut für Transfusionsmedizin, Frankfurt/M.
RECRUITING
Groupe Hospitalier Necker Enfants Malades, Paris
RECRUITING
UC Davis, Sacramento
RECRUITING
McGill University Health Center, Montreal
RECRUITING
IPS SURA Industriales Medellín, Medellín
RECRUITING
Universita' Degli Studi La Sapienza-Ist.Di Ematologia, Rome
RECRUITING
Nagoya University Hospital, Nagoya
RECRUITING
Erasmus MC, Rotterdam
RECRUITING
Instytut Hematologii i Transfuzjologii, Warsaw
Hoffmann-La Roche
INDUSTRY